New Strategies for Multimodality Therapy in Treating Locally Advanced Cervix Cancer.
Cervical cancer is the fourth most common cause of cancer of women worldwide. In the developing world, it comprises 12% of all cancers of women. Since 1999, the mainstay of treatment for locally advanced cervical cancer (LACC) has been concurrent cisplatin-based chemoradiation. However, outcomes in this disease remain suboptimal, with long-term progression-free survival and overall survival rates of approximately 60%. There are several new strategies of combined modality treatment under evaluation in LACC, including chemotherapy before and after treatment as well as novel agents such as poly-adenosine diphosphate ribose polymerase inhibitors, antiangiogenic blockage, and immunotherapy. We provide a brief overview of these strategies and their potential in the treatment of women with LACC.
Department of Radiation Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL.
Jonathan
J
Verma
Division of Gynecologic Oncology, University of Arizona Cancer Center at St. Joseph's Hospital, Phoenix, AZ.
Bradley J
BJ
Monk
Department of Radiation Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL. Electronic address: awolfson@med.miami.edu.
Aaron H
AH
Wolfson
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D002945:Cisplatin